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INTRODUCTION 
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INTRODUCTION 
 
The thyroid gland is situated anterior to trachea in lower part of the 
neck. It consists of right and left lobe connected across the median plane by 
isthmus. The thyroid parenchyma is composed of lobules of thyroid follicles 
with intervening thin fibrous tissue septae.Each follicle consists of central 
core of colloid surrounded by single layer of follicular epithelial cells. The 
parafollicular ‘C’ cells are located at the periphery of the follicles in small 
groups or as single cells. [1] 
The main function of thyroid gland is production of thyroid hormones 
T3 and T4 which regulates the cellular metabolism, oxygen consumption 
and protein synthesis. The parafollicular cells secrete calcitonin which in 
turn regulates the calcium level in the plasma by a feedback mechanism [1]. 
Thyroid neoplasms account for 1% of all malignancies and it is the 
most common among all endocrine malignancies [2].Environmental and 
genetic factors play a major role in thyroid neoplasms due to the 
dependence on iodine for hormone production. This organ is also vulnerable 
to the genotoxic effects of radioactive iodine and to the non-genotoxic 
effects caused by iodine deficiency [3], thereby resulting in neoplastic 
lesions. 
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With improved, technically advanced diagnostic screening procedures 
like guided FNA procedures, PET scan etc, detection of early neoplastic 
lesions are on the rise .When early neoplastic lesions are sampled from 
thyroid, morphological assessment to diagnose these, pose a significant 
challenge to pathologist and for treatment by the surgeons. 
Many a time morphology and immunohistochemistry is adequate for 
diagnosing neoplasms of thyroid, [4] but a significant number of thyroid 
neoplasms go unnoticed when early lesions are sampled. As genetic 
alteration is the earliest change that occurs in oncogenesis and it may be 
acquired in the due course of life, it is important to identify these for early 
treatment, prognostication and for prevention. Therefore the knowledge of 
genetic alteration will   help not only in detecting the genesis of thyroid 
carcinomas but also might help in treatment and prognostication. 
Recent data’s suggest that alterations in RAS-RAF-MAP kinase 
signaling pathway is seen in many neoplastic lesions of various organs but 
is more frequent in thyroid carcinomas. In papillary thyroid carcinoma 
BRAF mutation especially V600E mutation plays a vital role .Studies state 
[5, 6] that BRAF mutation is specific for papillary thyroid carcinoma and is 
frequently seen in high grade tumors and is associated with poorer 
outcomes.  
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We did a Pubmed search for articles on relevant areas. The number of 
articles returned for contain keywords in Pubmed search is Nil. (Limits; 10 
years, English language, humans).keywords used in MESH “Proto-
oncogene proteins B-raf/genetics” “Thyroid Neoplasms” and “India”. 
Thus there is paucity of Indian literature in the area of pathogenesis of 
neoplasms of thyroid. The fact that there is a need to establish and conduct 
scientific work linking proteins , genes and finding molecular markers for 
thyroid neoplasms emphasizes the importance of our work. As 1% of 
population world over suffers from thyroid neoplasms, research in this area 
would help in treatment, prognostication and possibly prevention of this 
major problem.  
Therefore we propose to study the prevalence of BRAF V600E 
mutation in thyroid neoplasms in PSGIMS&R and its association with 
various phenotypic features as an initial step. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
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AIMS AND OBJECTIVES 
 
The aims of this study are 
 
1.  To estimate the prevalence of BRAF V600E mutation in thyroid 
neoplasms diagnosed at a tertiary care hospital at Coimbatore. 
2. To correlate the BRAF V600E mutation with clinicopathological 
parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
 
The thyroid gland first appears as a median anlage and two lateral 
anlagen. The median anlage develops in the floor of primitive pharynx at the 
foramen cecum and grows caudally to become bilobed forming the greater 
portion of the thyroid gland and forms follicular epithelial cells. The two 
lateral anlagen derived from ultimobranchial bodies’ fuse with median 
thyroid anlage and become incorporated into the lateral lobes .Then the 
ultimobranchial bodies undergo dissolution phase and forms peripheral 
component of cell groups called C cells [1]. 
Thyroid neoplasms are the most common endocrine neoplasms and 
accounts for 1% of all human malignancies [2]. It usually occurs in the young 
and in the middle age group. It is more frequent in females [2, 3]. The relative 
frequency of papillary carcinoma is high in regions of adequate or high 
dietary iodine intake. In regions of iodine deficiency the incidence of 
papillary carcinoma is high after iodine supplementation [3]. In endemic 
goiter regions the prognosis for thyroid carcinoma is worse, when compared 
with regions with an adequate dietary iodine intake [7]. Even in regions with 
endemic goiters papillary neoplasms predominate over follicular cancers [3]. 
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A report from Health and family Welfare Department, Government of 
Tamilnadu [8] from their survey conducted from 1990, states that goiter is 
prevalent in all the districts.  18 districts out of 29 have more than 10 % 
prevalence. Coimbatore is included among the 18 districts, where the goiter 
prevalence is 11.7%. 
Studies from India state that papillary thyroid carcinoma is more 
common in coastal areas. A report by Professor, N.Dorairajan, on 
investigating thyroid cancer [9] states and I quote “In India, thyroid cancer 
has a widespread distribution with certain subtypes, notably papillary 
cancer, occurring in coastal areas of Tamil Nadu, Andhra Pradesh and 
Kerala which are iodine rich. The iodine content of soil modifies 
development of these cancers.”He also states “In South India, excess iodine 
in diet is related to the higher incidence of papillary cancer compared to 
other more malignant subtypes of thyroid cancer.”  
 The thyroid neoplasms are classified as given below. 
 
CLASSIFICATION OF THYROID TUMORS (WHO 2004) [3] 
         BENIGN           
Ø Follicular adenoma 
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         MALIGNANT 
Ø Papillary carcinoma  
Ø Follicular carcinoma  
Ø Medullary carcinoma                                                                                                                 
Ø Poorly differentiated carcinoma (Anaplastic) 
Ø Undifferentiated carcinoma (Insular) 
Ø Mucinous carcinoma 
Ø Muco- epidermoid carcinoma 
Ø Squamous cell carcinoma 
Ø Others 
FOLLICULAR ADENOMA: 
Follicular adenoma is a benign tumor enveloped by a thick fibrous 
capsule. Morphologically, it is composed of closely packed follicles, 
trabeculae or solid sheets of cuboidal cells with pale or darkly stained nuclei 
and inconspicuous nucleoli.  
Rare variants like atypical follicular adenoma, hyalinizing trabecular 
adenoma and Signet- ring cell follicular adenoma [10] are also reported. 
Increase in cellularity, mitoses, spontaneous necrosis or infarction but lack 
of invasion into the capsule or vasculature are the characteristic features of 
atypical follicular adenoma.  
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Hyalinizing trabecular adenoma is characterized by elongated tumor 
cells arranged in a wavy trabecular pattern around capillaries. Nuclear 
grooves, pseudoinclusions and peri nuclear haloes are prominent. 
Predominance of signet ring cells with abundant cytoplasmic vacuoles, 
intermixed with groups of follicular cells of normal cytologic features are 
the findings reported in Signet- ring cell follicular adenoma. 
Hurthle cell adenomas are considered a subtype of follicular 
adenoma. They are bright brown in a gross appearance. This neoplasm is 
characterized by the presence of Oxyphilic/Hurthle cells arranged in 
follicular and or trabecular pattern with partial or complete encapsulation 
morphologically; the Hurthle cells are large cells with abundant eosinophilic 
granular cytoplasm and a round nucleus. Accumulation of abundant 
mitochondria gives a granular appearance to the cytoplasm under the light 
microscope. It has a tendency for spontaneous infarction [11]. 
PAPILLARY CARCINOMA: 
The most common of all primary thyroid malignancies is papillary 
carcinoma, accounts for about 70- 85% of cases [12]. It can occur in any age 
and has a female preponderance. Multifocal disease along with 
intrathyroidal extension and metastasizes to regional lymph nodes are the 
characteristic features. Extra thyroidal extension can occur and extend 
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beyond the capsule of the thyroid gland to involve structures like larynx, 
trachea or esophagus.  
Papillary carcinoma classic type is characterized by formation of 
complex arborizing papillae with a central fibro vascular core under the 
light microscope. The papillae are covered by cells with crowded oval 
nuclei. The nuclei show margination of chromatin, overlapping, with 
nuclear grooving and intra nuclear cytoplasmic pseudo inclusions. However, 
papillary thyroid carcinoma can exhibit a pure follicular pattern or mixed 
papillary and follicular pattern. Psammoma bodies are nothing but the 
lamellated concretions formed by deposition of calcium is one of the most 
important finding in papillary carcinoma [13]. 
The relationship between Hashimoto’s thyroiditis and papillary 
carcinoma is controversial. Reports by Livolsi [14] suggested that the 
lymphocytic infiltration of the surrounding thyroid tissue is induced through 
autoimmune mechanisms triggered during the development of papillary 
carcinoma. Harach et al [15] found that lymphocytic thyroiditis more 
commonly associated with papillary thyroid carcinoma than with other types 
of thyroid carcinomas. But a study conducted by Dubravka [16] et al showed 
no significant association between Hashimoto’s thyroiditis and Papillary 
carcinoma. 
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VARIANTS OF PAPILLARY CARCINOMA: 
Several morphological variants of papillary carcinoma have been 
recognized based on the architecture, growth pattern, cellular morphology 
and stromal features. The subtypes are important as some of these subtypes 
are more aggressive in their biologic and clinical behaviour irrespective of 
their bland appearance. [11] 
I. Papillary microcarcinoma: 
Papillary micro carcinomas usually measures 1 cm or less in diameter 
and often unencapsulated. It is detected incidentally in thyroidectomy 
specimens for other indications and is associated with an excellent 
prognosis though occasional regional lymph node metastasis is usual [11]. 
 II. Follicular variant:  
This neoplasm composed of small to medium sized, irregularly 
shaped follicles with abortive papillary formation. Stromal sclerosis and 
psammoma bodies can be present. Characteristic nuclear features of 
papillary carcinoma are evident. Distant metastasis and vascular invasion 
are common. Some of these tumors exhibit encapsulation with an 
exceptionally good prognosis (so called Lindsay tumor) [11].  
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III. Tall cell variant: 
This is a rare variant and is composed of tumor cells whose heights 
are at least three times their widths. Tall cells must be seen in 50% or more 
of the tumor areas to make a diagnosis of tall cell variant of papillary 
thyroid carcinoma [11] Necrosis, mitotic activity and extra thyroidal 
extension are common. These tumors occur in older patients, often males, 
with a more aggressive clinical behaviour. This variant is commonly 
associated with BRAF mutation reflects its aggressiveness [17]. 
IV. Oncocytic variant: 
This variant of papillary carcinoma comprising of complex branching 
papillae with thin fibrovascular stromal core, covered by polygonal 
oncocytic cells with abundant granular eosinophilic cytoplasm.[13]The 
behaviour is similar to conventional papillary carcinoma.     
V. Warthin tumor like variant: 
The characteristic feature of this variant is brisk lymphoplasmacytic 
infiltrate in the papillary stalks. Papillae were lined by oncocytic cells with 
the typical nuclear features of classic papillary carcinoma.  It is frequently 
associated with Hashimoto thyroiditis [11].  The immuno profile of the 
lymphoid cells is no different from chronic lymphocytic thyroiditis. 
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VI. Cribriform variant: 
Predominant cribriform pattern, focal papillary architecture, solid and 
spindle cell areas interspersed with squamoid morules, characterize this 
uncommon variant of papillary carcinoma [12]. The nuclei frequently harbor 
eosinophilic, homogenous cytoplasmic inclusions. It typically occurs in 
patients with familial adenomatous polyposis or Gardner syndrome. This 
tumor is often multifocal and occurs in young women. 
VII. Diffuse sclerosing variant: 
This rare variant of papillary carcinoma seen more frequently in 
children and is associated with a poor prognosis [12]. The typical finding of 
this tumor includes diffuse involvement of both the lobes, dense 
lymphoplasmacytic infiltrate with extensive lymphatic permeation.   
VIII. Clear cell variant: 
Tumor cells have extensive clear or vacuolated cytoplasm. 
Cytoplasmic clearing is usually due to accumulation of glycogen [10]. The 
nuclear features are otherwise typical of papillary carcinoma.  
FOLLICULAR CARCINOMA: 
It accounts for 5-15% of all thyroid malignancies. The tumor can be 
encapsulated or widely invasive. A true capsular and / or a vascular invasion 
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in a follicular neoplasm are mandatory to diagnose follicular carcinoma. It is 
more common in an older age group and more common in females. [10, 13] 
The criteria to diagnose follicular carcinoma include invasion of the 
capsule, invasion through the capsule and invasion into vein in or beyond 
the capsule [11]. 
Tumors with limited focal capsular and / or vascular invasion that are 
apparent only on histological examination are termed as ‘Minimally 
invasive follicular carcinomas’. ‘Follicular tumors of uncertain malignant 
potential’ are designated, if the presence or absence of invasion is not 
certain or unequivocal. 
Tumors with infiltrative margins and extensive vascular invasion (>4 
blood vessel) are the features of widely invasive follicular carcinoma         
[10, 11]. 
Follicular carcinomas lack multifocality and do not invade 
lymphatics. But it can metastasize hematogenously to bone and lungs. The 
metastatic lesions from follicular carcinoma are histologically similar to the 
primary neoplasm in the thyroid. It can also be deceptively bland and mimic 
normal thyroid tissue. 
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MEDULLARY CARCINOMA: 
Medullary carcinoma is a malignant tumor of C cell origin and is of 
great diagnostic importance because of its aggressiveness. It comprises less 
than 10% of all malignant thyroid malignancies [11]. Calcitonin secretion is 
characteristic. It occurs in the setting of several inherited cancer syndromes 
including multiple endocrine neoplasia (MEN) syndromes. Medullary 
carcinoma can exhibit trabecular, insular or sheet like growth patterns 
traversed by delicate fibro vascular septa. The cells are small with stippled 
chromatin. The tumor stroma characteristically contains Amyloid. Tumor 
necrosis and mitotic figures are infrequent. Lymphatic invasion and extra 
thyroidal involvement by direct extension can be present.  
 
POORLY DIFFERENTIATED CARCINOMA: 
Poorly differentiated thyroid carcinoma or insular carcinoma usually 
occurs in an older age group and it represents a heterogeneous group of 
malignant neoplasms, with varied growth patterns and biological behaviour. 
It grows in the form of nests and solid to microfollicular arrangement. The 
cells are small, uniform with hyper chromatic or vesicular nucleus and 
variable mitotic activity [13].Prominent vascularization, coagulative necrosis, 
infiltrative growth pattern and obvious vascular invasion are characteristic.  
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 Age more than 45 years; tumor necrosis and mitotic count of more 
than 3 per 10 high power fields have been associated with the aggressive 
biological behavior. 
ANAPLASTIC CARCINOMA: 
Anaplastic carcinoma or undifferentiated thyroid carcinoma is a rare 
aggressive tumor accounts for about 5 - 10% of all malignant tumors of 
thyroid [10].The tumor is usually seen in older patients and in iodine deficient 
areas with a rapidly enlarging mass with compression symptoms. Anaplastic 
carcinoma exhibits a wide range of morphologic patterns and cell types, 
predominant being epithelioid cells, spindle cells and giant cells with focal 
squamoid differentiation. The tumor cells exhibit marked anaplasia and also 
shows frequent mitoses, extensive coagulative necrosis and marked degree 
of invasion into the surrounding soft tissues [3]. Distant metastasis is 
frequent. A pre-existing well differentiated thyroid neoplasm, more often 
follicular or papillary carcinoma is usually seen in many, if not in most of 
the undifferentiated carcinomas. 
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TNM CLASSIFICATION AND STAGING OF THYROID 
CARCINOMAS  
The staging of the disease explains the spread of cancer and grading 
gives the level of differentiation, in combination, these determine clinical 
gravity of the disease. The TNM system is endorsed by the International 
Union against Cancer (UICC) and the American Joint Commission on 
Cancer (AJCC) are commonly used. The staging of thyroid neoplasms is as 
given below [3] 
 
T- Primary Tumor 
TX:    Primary cannot be assessed. 
T0: No evidence of primary tumor. 
T1: Tumor 2 cm or less in greatest dimension, limited to thyroid. 
T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension,     
limited to thyroid. 
T3: Tumor more than 4 cm in greatest dimension, limited to thyroid or 
any tumor with minimal extra thyroidal extension (e.g. extension to 
sternothyroid muscle or perithyroid soft tissues) limited to the 
thyroid. 
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T4a: Tumor extends beyond the thyroid capsule and invades any of the 
following: subcutaneous soft tissues, larynx, trachea, esophagus, 
recurrent laryngeal nerve* 
T4b: Tumor invades prevertebral fascia, mediastinal vessels, or encases 
carotid artery* 
 
T4a*    (Anaplastic carcinoma only) Tumor (any size), limited to the 
thyroid** 
T4b*    (Anaplastic carcinoma only) Tumor (any size), extends beyond the 
thyroid capsule***. 
Notes:  
        Multifocal tumors of all histological types should be designated (m). 
* All Anaplastic/undifferentiated thyroid carcinomas are considered T4. 
** Intrathyroidal anaplastic carcinoma – considered surgically resectable.     
*** Extra thyroidal anaplastic carcinoma – considered surgically 
unresectable. 
 
N-Regional Lymph Nodes 
NX:  Regional lymph nodes cannot be assessed. 
N0: No regional lymph  node metastasis. 
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N1:  Regional lymph node metastasis. 
N1a: Metastasis in Level VI (pretracheal and paratracheal, including 
prelaryngeal and Delphian lymph nodes). 
N1b: Metastasis in other unilateral, bilateral or contra lateral cervical or 
Upper/ superior mediastinal lymph nodes. 
 
M – Distant Metastasis 
MX: Distant metastasis cannot be assessed. 
M0:  No distant metastasis 
M1: Distant metastasis 
 
STAGE GROUPING: 
               For papillary and follicular, medullary and anaplastic/ 
undifferentiated carcinomas separate stage groupings are recommended. 
Unlike most other cancers, thyroid carcinomas are grouped into stages in a 
way that considers both the subtype of the neoplasm and the patient’s age [3]. 
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Papillary or Follicular under 45 years 
Stage I                 Any T             Any  N              M0 
Stage II   Any T Any 
N                    
M1 
 
Papillary or Follicular, 45 years and older and Medullary of any age 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3  
T1, T2, T3 
N0  
N1a 
M0 
M0 
Stage IVA T1, T2, T3  
T4a 
N1b  
N0, N1 
M0  
M0 
Stage IVB T4b Any N M0 
Stage IVC Any T Any N M1 
 
Anaplastic/ Undifferentiated (all are considered stage IV) 
Stage IVA T4a Any N M0 
Stage IVB T4b Any N M0 
Stage IVC Any T Any N M1 
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GRADING: 
Tumor grading in thyroid malignancies is of little significance as 
more than 95% of cases are well differentiated using standard grading 
criteria [3]. Certain variants such as tall cell variant and diffuse sclerosing 
variants of papillary thyroid carcinoma are associated with an aggressive 
clinical behaviour. Biological behaviour of follicular carcinoma can be 
assigned based on tumor size, local extension and presence of distant 
metastasis. Poor survival of medullary carcinoma [13] is determined by the 
presence of necrosis, squamous metaplasia and distant metastasis.  
 
MOLECULAR ALTERATIONS IN THYROID MALIGNANCY: 
Hundreds of cancer associated genes have been discovered over the 
past two decades. The identification of genes and pathways involved will 
not only enhance our understanding of the biology of this process, it will 
also provide new targets for early diagnosis and facilitate treatment design.             
Cancers arise owing to the accumulation of mutations in critical genes 
that alter normal programmes of cell proliferation, differentiation and death. 
Several molecules that are involved in the pathogenesis of thyroid 
cancers are emerging as diagnostic and or prognostic tool for patient 
management. Among all thyroid malignancies, papillary carcinomas 
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commonly have one of the following genetic alterations: BRAF point 
mutations RET/PTC rearrangements or RAS point mutations [18].  
Follicular carcinoma is frequently associated with PAX8/PPARγ 
fusion gene and loss of heterozigosity on 3p and 7q loci as well as RAS 
mutations [18]. Activating germline point mutations of RET [17] is a feature of 
medullary carcinoma are present in 95% of patients with MEN 2. 
Poorly differentiated and undifferentiated thyroid cancers have been 
associated with inactivating mutations of p53, CTNNB1 mutations, and 
BRAF and RAS mutations.RET rearrangement is associated with poorly 
differentiated thyroid tumor not in anaplastic carcinoma [19]. 
BRAF: AN OVERVIEW 
BRAF is a Serine - Threonine kinase that belongs to the family of 
RAF (20) proteins. It acts upstream of the MEK1/2 kinases in response to 
RAS signals. 
Structurally RAF protein is divided into two functional domains , the 
N - terminal regulatory domain and C- terminal regulatory domain  with 
three conserved region (CR 1,2 and 3).CR1 and CR2 being present in N 
terminal domain and CR3 is situated in C terminal domain [21]. 
Normally in a cell RAS proteins are attached to the plasma membrane 
on the cytoplasmic aspect, the endoplasmic reticulum and the Golgi 
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membrane. They are activated by the growth factor binding to its receptors 
.In the inactive state, RAS proteins are bound to GDP. If there is any 
stimulation ,exchange of GDP to GTP occurs leading to conformational 
change that produces active RAS[2].The activated RAS binds to the RAS 
binding domain in CR1 of RAF and recruits RAF to the membrane .This 
activates downstream signaling cascade[21]. RAF phosphorylates the 
mitogen –activated protein kinase (MAPK). 
Extracellular signal-regulated kinases MEK 1 and 2 gets activated 
which in turn phosphorylates and activates extracellular signal regulated 
kinases ERK 1, and 2. Activated ERK migrates to the nucleus. In the 
nucleus, it activates various transcription factors leading to cell cycle 
progression which results in cell proliferation and differentiation [22] (Fig 1). 
The RAF protein has three isoforms, A-RAF, B-RAF and C-RAF 
.Among these BRAF is commonly found in thyroid follicular cells [19]. B-
RAF has a higher basal kinase activity when compared to other isoforms. 
Since serine 445 is constitutively phosphorylated in BRAF, a single 
mutation at codon 600 results in constitutive activation of BRAF in human 
cancers [21, 23].  
BRAF protein is expressed in higher levels in hematopoietic cells, 
neurons, testicles and is the predominant isoform [19] in thyroid follicular 
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cells and is the most potent activator of the MAPK pathway. Gain-of-
function BRAF mutation provides an alternative route for the aberrant 
activation of ERK signaling resulting in constitutive activation of BRAF 
kinase that means it is able to phosphorylate MEK as monomers in a RAS 
independent manner and chronic stimulation of MAPK pathway resulting in 
increased proliferation , decreased survival and differentiation of cells[24] 
(Fig 1). 
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Fig 1: Mechanism of BRAF  
 
                                    GF 
                                     GF Receptor                
 
 
 
                                                                       GDP               GTP                                         
 
 
 
 
 
 
 
 
 
 
  
 
 This mechanism is implicated in the tumorigenesis of several human 
cancer for example malignant melanoma , thyroid carcinoma ,colorectal 
GF-Growth Factor; GDP-Guanosine diphosphate; GTP- Guanosine-triphosphate;   
MAPK-Mitogen-Activated Protein Kinase   
BRAF 
Cell cycle progression  
 
Active   
RAS 
Inactive 
RAS 
Plasma membrane 
Activation of Transcription Pathway 
Increased Cell proliferation 
Activation of MAPK   Pathway 
Mutation 
Constitutive 
activation  
Chronic stimulation of   
MAPK Pathway 
25 
carcinoma , ovarian carcinoma  and carcinomas of  biliary tract, ovary, 
colon , endometrium ,liver , breast, pancreas and cervix[21,25] .  
BRAF EXPRESSION IN THYROID CARCINOMAS: 
Many a time diagnosis of thyroid malignancy can be reached by 
morphological assessment alone. Immunohistochemical study will be useful 
if the tumors exhibit unusual patterns to confirm diagnosis and to establish 
the prognosis.  
There has been a significant improvement in the knowledge of 
molecular alterations over the last two decades in all tumors including 
thyroid malignancies. Oncogenic BRAF activation represents the most 
prevalent molecular alterations.  
BRAF mutations are involved in early thyroid carcinogenesis but it is 
not a germline mutation instead it is a somatic genetic alteration [26].  
The BRAF mutation occurs early and plays an important role in the 
pathogenesis of papillary thyroid carcinoma in which point mutations of the 
BRAF gene are the most common mutation to occur in about 40 - 45 % [24]. 
According to some literature [27] incidence of BRAF mutation in papillary 
thyroid carcinoma is 35%-69% of PTC. 
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Most common mutation of BRAF is V600E. Here the missense 
thymine(T) to adenine (A) transversion at nucleotide 1799 in exon 15 occur, 
resulting in the substitution of a valine by glutamate at residue 600 . The 
less common mutation being the K601E mutation found in thyroid  
cancer[28]. 
Many studies have found that BRAF mutation is associated with 
poorer clininopathologic outcome [17, 29, 30]. A study conducted by Henderson 
et al found that recurrent papillary thyroid carcinoma is significantly 
associated with predominant BRAF mutation [31]. 
Among various subtypes BRAF mutation occurred most commonly in 
tall cell variant of PTC followed by conventional PTC and less commonly 
in follicular variant of papillary thyroid carcinoma. The Tall cell variant 
being the aggressive tumor indicating that BRAF mutation associated with 
poorer outcome [26, 32].Cristiana Lupi et al in their study they concluded that 
BRAF V600E mutation was found to be associated with follicular variant of 
papillary thyroid carcinoma with invasive tumor growth[33]. 
Other association between mutation and aggressive tumor phenotype 
include older age, extrathyroidal tumor invasion, lymph node and distant 
metastasis, higher tumor stage stage and poorly different cancer [34, 35]. 
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However, in some study BRAF V600E mutation was found to be in patients 
with young age group [20]. 
F.Frasca et al [36] in their study found that presence of BRAF V600E 
mutation in PTC s is associated with aggressive tumor behaviour. They also 
found that the tumor aggressiveness is independently of tumor size 
suggesting that small BRAF positive tumors carry higher risk of progression 
and invasiveness than the BRAF negative tumors. 
BRAF mutation can be readily tested on thyroid fine needle aspiration 
biopsy specimens, with high preoperative predictive probabilities for 
clinicopathological outcomes of papillary thyroid carcinoma[37].But it has 
limited diagnostic value because [29,38]of the low sensitivity of BRAF 
mutation when used in cytologically indeterminate specimens that are 
mostly non-PTC and therefore do not harbor BRAF mutation. 
However controversies regarding BRAF mutations with poorer 
clinico pathologic outcome of papillary thyroid cancers have been reported 
in some studies [39, 40].  
In thyroid, apart from papillary carcinoma BRAF mutation is also 
expressed in anaplastic carcinoma and poorly differentiated carcinoma and 
the prevalence is 20-30% and 10-15 % respectively. According to literatures 
[19] BRAF mutated poorly differentiated and anaplastic carcinoma will have 
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papillary component. This finding implies that these tumors may progress 
from BRAF positive papillary carcinoma. 
BRAFV600E mutation is commonly not found in follicular thyroid 
cancer and benign thyroid nodules [32]. But BRAF K601E mutation was 
detected in follicular adenoma, carcinoma, and follicular variant of PTC. 
However Electron et al in their study they observed that BRAF V600E 
mutation was expressed in one case of follicular carcinoma [35]. 
With these as background we proposed to do a study in BRAF V600E 
mutation in various thyroid neoplasms at PSGIMS&R a tertiary care 
hospital, Coimbatore. 
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MATERIALS AND METHODS 
 
All cases diagnosed as a thyroid neoplasm from Jan 2006 to Sep 2009 
in the Department of Pathology, PSG Institute of Medical Sciences and 
Research, Coimbatore were considered for this study.  
The clinical details of these cases were taken from the medical 
records department of PSG IMS&R, after obtaining permission from the 
authorities and due IHEC clearance. Age, sex, clinical presentation and 
hormone status were obtained by analyzing the case records.  The T and N 
status of the malignant neoplasms was also noted for staging.              
The H&E slides of all the cases were analyzed for the following: the 
type of neoplasm, various nuclear features, invasion into the capsule and 
vascular spaces, extra thyroidal extension, lymph node metastases, mitoses, 
necrosis and presence or absence of Amyloid. Paraffin blocks of those 
sections which had high tumor density with less normal thyroid tissue were 
included for the study by using H&E stained slides. Paraffin blocks of slides 
which showed tumor with large areas of hemorrhage, cystic change and 
necrosis were excluded from the study. 
Two primers (Forward and Reverse primers) were designed to 
amplify a fragment of the exon 15 of BRAF containing site where the 
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V600E mutation occurs.Polymerase Chain Reaction and Restriction 
Fragment Length Polymorphism (RFLP) method were carried out for 
mutation detection. 
The following steps were followed in the methodology. (Fig 2) 
 
STEP 1: 
TISSUE PREPARATION FROM FORMALIN FIXED PARAFFIN    
EMBEDDED (FFPE) BLOCKS [38] 
1) Using a pen, the area of the tissue containing the maximum tumor was 
marked on hematoxylin-eosin stained slide. 
2) 10-15 μm sections were cut from formalin fixed paraffin embedded 
tissues and placed over the plain glass slide. 
3)  The sections were deparaffinized by immersion in xylene, followed by 
hydrated in graded alcohol 
4) The H&E stained slide with the marked tumor area was kept over the 
unstained section slide. 
5) Using the circled area of interest on the unstained tissue section slide as a 
guide, a   clean scalpel blade was used to scrape the tissue in the area 
containing tumor tissue  
6) The tissue was placed in a 2 ml of Eppendorf tube. 
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STEP 2: 
 ISOLATION OF DNA FROM FFPE 
 PROCEDURE: PHENOL CHLOROFORM METHOD 
After placementment of tissue in Eppendorf tube, we dried the tissues 
at 50oC, followed by we added 500 µL lysis buffer and 35 µL Proteinase K 
(20mg/mL) in each tube .Then the solution was incubated at 60oC for 2-3 
hours or until the tissue dissolves. Then we raised the temperature to 95 o C. 
Inactivation of Proteinase K was done by incubating the tube for 8 
min and then    15 µL RNase (10mg/mL) was added to each tube, followed 
by it kept it for incubation at 37 oC for 15 minutes. 
Phenol: Chloroform (1ml) was added to each tube and then the 
solution was mixed properly. We centrifuged the mixture at 13,000 RPM for 
5 minutes, then the supernatant was transferred to fresh tube then we added 
equal volume of choloroform and vortexed vigorously, again centrifuged at 
13,000RPM for 5 minutes, supernatant was collected in a fresh tube .50 µL 
of 30M sodium acetate and 1mL of 100% ethanol added again, 
centrifugation was done at the same RPM and time as mentioned above and 
then the supernatant was discarded. 
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Finally the pellet was washed in 75% ethanol, followed by 
centrifugation at maximum RPM for 5-10 minutes was done. We dried the 
pellet and suspension of pellet in 35 µL of Milli Q. 
The end product was run on an Agarose gel electrophoresis to check 
for the success of DNA isolation process (Fig 3). 
 
STEP 3:  
PCR OF ISOLATED DNA USING BRAF PRIMERS  
PCR by using BRAF 15F and 15R primers was done to amplify a 224 
bp fragment of the exon 15 of BRAF[39] containing the site in which V600E 
mutation occurs. PCR reaction were performed in 25 µl of 1.5 mM Mgcl2 
with 200µM deoxynucleoside triphosphates ,50-100 ng DNA,0.5 µM of 
each primer and 2.5 U Taq polymerase. 
Forty cycles with annealing temperature optimized at 59 o C were 
used to apply PCR product .PCR amplification was confirmed on 2% 
Agarose gel (Fig 4) .The PCR product size was 224 bp.  
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STEP 4:  
CLEAN UP OF PCR PRODUCT  
PROCEDURE: 
We used HIPURA-HIMEDIA clean up kit for this procedure.  
        1.5 ml of PCR product was taken in a tube and we added 4.5 volume of 
SBP binding solution (PCR binding solution), mixed thoroughly by gentle 
pipetting. Loading of lysate in Miniprep spin column followed by 
centrifugation at 10,000 x g for a minute at room temperature was done. We 
discarded the flow through. 
Similar procedure was done by using 700µL of diluted wash solution 
(HPE) and 500 µL of diluted wash solution (HPE).Finally the empty tube 
was centrifuged for 2 minutes at 13,000 x g to dry column matrix, and then 
we transferred the column to new 2 ml tube, 30-50 µL of elution buffer was 
added. To elute DNA, centrifugation at 13,000 x g for 1 minute was done. 
Then we quantified the DNA by using Nanodrop. 
 
STEP 5:  
RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP) 
RFLP was carried out by digesting the PCR product with TspRI fast 
digest (Fermentas). This enzyme digests the wild type alleles and the bands 
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are seen as 120 and 104 bp respectively. We incubated the product at 65⁰C 
for 1 1/2 hours and the product was checked in 12 % Polyacrylamide gel 
Electrophoresis (PAGE). 
Polyacrylamide gel was run in Amersham electrophoresis system at 
100 V for about 5 hours and the gel was stained with ethdium bromide.we 
viewed the stained gel in a Chemiluminescence gel documentation system 
to identify the DNA fragments.  The wild type alleles are visualized as two 
bands digested by the enzyme. (Fig 5) 
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Fig 2:  STEPS IN BRAF MUTATION ANALYSIS IN 
VARIOUS THYROID NEOPLASMS 
   
                         
 
                                                                      
                        
 
 
                           
 
 
 
  
          
  
 
 
 
 
Step 1              Tissue Preparation (FFPE) 
Step 2 DNA Extraction (Phenol Chloroform Method) 
 
Step 3          PCR using 15F &15R primers 
 
Step 4         Purification of the PCR product 
 
Step 5         Mutation detection by RFLP Assay 
FFPE – FORMALIN FIXED PARAFFIN EMBEDDED TISSUE; PCR-POLYMERASE CHAIN 
REACTION; 
RFLP-RESTRICTION FRAGMENT LENGTH POLYMORPHISM. 
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RESULTS   
        Department of pathology, PSGIMS&R received 15,739 biopsy 
specimens over a period of 3 years and 9 months (January 2006 to 
September 2009) of which 2953 were reported as malignant lesions. Of 
these 2953 malignancies 64 were thyroid neoplasms giving an overall 
incidence of 2.16%.  50 cases were selected from these 64 using the 
inclusion and exclusion criteria as mentioned before. The breakup of various 
types of thyroid neoplasms is as given in chart I.  
CHART I: Types of Thyroid Neoplasms: 
        Total number of cases: 50 
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17
2 1
PAPILLARY 
CARCINOMA
FOLLICULAR 
NEOPLASMS
MEDULLARY 
CARCINOMA
ANAPLASTIC 
CARCINOMA
 
      The age at presentation of these thyroid neoplasms ranged from 20-70 
years as given in the Chart II below, with the mean age of 45 years. There 
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was a female preponderance of thyroid neoplasm reported as shown in Chart 
III. 
CHART II.  Thyroid Neoplasms- Age Distribution 
            Total number of cases: 50 
 
CHART III: Thyroid Neoplasms- Sex Distribution  
Total number of cases 50 
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Among 50 case0s, 42 patients were in euthyroid state, 3 were 
hyperthyroid and 3 were in hypothyroid state and for 2 patients, hormone 
status was not available as shown in TABLE I. 
TABLE I: Thyroid Neoplasms- Hormone Status 
Hormone status Euthyroid Hypothyroid Hyperthyroid Not available Total  
No of cases 42 3 3 2 50 
The gross features of these thyroid neoplasms studied are as given 
below.  
The size of the tumor ranged from 0.4 to 11.5 cm and Table II shows 
the details of the size ranges and the types of thyroid neoplasms .The size of 
the tumour is essential for staging the neoplasms. 
TABLE II: Thyroid Neoplasms-Size Variation 
Size 
Papillary 
carcinoma 
Follicular 
neoplasm 
Medullary 
carcinoma 
Anaplastic 
carcinoma 
<2cm 13 1 0 0 
2 – 4 cm 13 10 2 0 
>4 cm 3 6 0 1 
Not assessed 1 0 0 0 
Total (50) 30 17 2 1 
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Cystic changes were observed in 6 cases of papillary carcinoma. 
Multifocality was noted in 10 cases and 2 patients had lymph node 
involvement. Extrathyroidal extension was found in 2 cases. 
 
All 17 cases of follicular neoplasms had a thick fibrous capsule 
around. Both the cases of medullary carcinoma had lymph node 
involvement. The lone case of anaplastic carcinoma measured 11.5 cm and 
involved right lobe and isthmus and also showed extrathyroidal extension. 
H&E stained slides were analyzed for the following, microscopic features, 
(i)     Architectural pattern  
(ii)     Nuclear atypia 
(iii) Vascular invasion 
(iv) Capsular invasion 
(v)      Mitotic activity 
(vi) Necrosis 
(vii) Presence of Amyloid deposits in case of medullary carcinoma. 
Among 30 cases of papillary thyroid carcinoma reported, 23 were 
papillary carcinoma classic type (Fig 6), 6 were micropapilary carcinoma 
(Fig 7) and the remaining one was encapsulated follicular variant of 
papillary carcinoma (Fig. 8) as shown in table III. 
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TABLE III: Thyroid Neoplasms – Papillary Carcinoma Variants 
Papillary Ca No of cases 
Classic  type     23 
Micro carcinoma variant      6 
Encapsulated Follicular variant      1 
Total      30 
     
Papillary thyroid carcinomas were also analyzed for the following 
microscopic features and scoring was done, according to Adebowale 
J.Adeniran et al [41]. 
1. Nuclear enlargement 
2. Irregularity of nuclear membrane 
3. Chromatin clearing 
4. Nuclear crowding /overlapping 
5. Nuclear grooves 
6. Nuclear pseudoinclusions  
7. Fibrosis 
8. Psammoma bodies 
9. Inflammatory response  
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The presence of first five features in the sections confined the 
specimens into the following scoring categories. If none of the features were 
observed the score given is 1, if <10 % of the section studied show above 
features  the score is 1+, if the section studied revealed  10-50% or >50% of 
the above features the scoring was graded as 2+ and  3+ respectively. 
The presence of pseudoinclusions were scored as given below .Score 
0-No pseudoinclusions /10HPF, Score 1+-1-2 pseudoinclusion /10HPF, 
Score 2+ - 3 to 5 pseudoinclusion /10HPF  and Score 3+ - >5 
pseudoinclusions found in 10 high power fields.  
Presence of tumor fibrosis was scored as 0, 1+, 2+, and 3+ for none, 
mild, moderate and severe respectively. Presence of inflammatory response 
(Chronic inflammatory cell aggregates)  and Psammoma bodies were 
counted for 10 HPF was scored as 0, 1+ , 2+ and 3+ for 0,1,2 to 5, and > 5 
respectively and was correlated with BRAF positive cases as shown in table 
Out of 17 cases of follicular neoplasms, 13 cases were folicular 
adenoma and 4 were follicular carcinoma. Of the 13 follicular adenomas, 11 
were   usual type (Fig 9), 1 was signet ring cell type (Fig 10) , and the 
remaining one was follicular adenoma with papillary architecture. Among 4 
cases of follicular carcinoma, 2 were  minimally invasive (Fig 11) , one was 
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Hurthle cell neoplasm (Fig 12) with focal capsular invasion and one was 
follicular neoplasm of uncertain malignant potential. (Fig 13) 
 
TABLE IV : Follicular neoplasm and its variants. 
                            Type of neoplasm No of cases 
Follicular 
adenoma 
n=12 
Usual type      11 
Micro follicular adenoma- signet ring cell type       1 
Follicular adenoma with papillary architecture       1 
Follicular 
carcinoma 
 n = 4 
Minimally invasive follicular carcinoma       2 
Hurthle cell neoplasm with capsular invasion        1 
Follicular neoplasm of Uncertain malignant 
potential 
      1 
               
Both cases of medullary carcinoma showed the cells  in nests and 
sheets (Fig 14)along with  amyloid in the stroma (Fig 15), as proven by 
congored staining and by polarized microscopy.The single case of 
Anaplastic carcinoma of thyroid showed solid pattern of arrangement of 
cells with marked pleomorphism , increased mitotic rate,necrosis and 
evidence of  invasion into the adjacent muscle fibers.(Fig16) 
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Staging of these was done according to TNM classification and is as 
given in the table V and chart IV.  
 TABLE V:  Thyroid Neoplasms - Stage at Diagnosis 
Stage 
Papillary 
carcinoma 
Follicular  
neoplasms 
Medullary 
carcinoma 
Anaplastic 
carcinoma 
I 14 17 0 0 
II 9 0 0 0 
III 7 0 0 0 
IVa 0 0 2 0 
IVb 0 0 0 1 
Total (50) 30 17 2 1 
 
      CHART IV: Thyroid Neoplasms - STAGE AT DIAGNOSIS 
            Total number of cases 50 
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BRAF MUTATION - RESULTS: 
           Out of 50 cases studied, DNA could be extracted from 47 cases only. 
DNA extraction was not possible for the 3 cases. Of these 47 cases, 14 cases 
expressed BRAF mutation. Among these 14, 9 were papillary carcinomas 
and 5 were follicular neoplasms.  Out of 5 positive follicular neoplasms, 3 
were follicular adenoma and the other 2 were follicular carcinoma as shown 
in table VI. 
TABLE VI:  BRAF V600E Positive Cases and Type Of Thyroid Neoplasms 
 
        Papillary carcinoma          Folicular neoplasm    Total 
Conventional type Encapsulated 
follicular variant 
Follicular 
Adenoma 
Follicular 
Carcinoma 
 
 
14            8          1       3           2 
 
The BRAF V600E mutated cases were analyzed with various 
phenotypic features and the results are given in chart V, VI and VII and in 
table VII. 
Out of 9 cases of BRAF positive papillary carcinomas, 5 cases were 
between the age group of 20-30 yrs and one case each in the 3rd, 4th,5th and 
6th decade. 
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CHART V   :  Number of  BRAF Positive Papillary Thyroid Carcinoma - 
Age Distribution n=9     
 
 
 
 
 
 
 
 
Out of the 9 cases of BRAF positive papillary thyroid carcinomas 8 
were females as shown in TABLE VII. 
TABLE VII:  Carcinoma - Sex Distribution 
    Sex BRAF Positive PTC 
   Male         1 
  Female         8 
  Total         9 
 
        Out of 9 patients 8 patients were in euthyroid state (88.88%) and 1 in 
hypothyroid state as shown in Chart VI. 55.55% of BRAF V600E positive 
5
1
1
1
1 20-30
31-40
41-50
51-60
61-70
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cases  found to be in stage I( 5/9 cases), stage II was present in 3 cases 
(33.33%) and 1 case was found in stage III as given in chart VII. 
CHART VI:  Number of BRAF Positive Papillary Thyroid Carcinoma-
Hormone Status 
  
 
CHART VII:  Number of BRAF Positive Papillary Thyroid Carcinoma - 
Stage at Presentation 
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Scoring for nuclear features and other microscopical features revealed 
consistent nuclear features in BRAF positive Papillary Carcinoma s as 
shown in Table VIII 
TABLE VIII: Scoring for nuclear and other microscopical feature - BRAF 
positive papillary carcinoma  
S. No NE NI CC NC NG 
PI 
/10HPF 
Fib 
PB 
/10HPF 
Inflammatory 
Cell aggregate 
/10HPF 
1 1 1 2 3 3 0 1 2 1 
2 2 1 3 3 2 0 0 0 0 
3 2 1 3 3 2 1 1 0 0 
4 2 2 1 3 2 2 1 0 0 
5 2 1 3 2 2 1 1 0 0 
6 2 1 3 2 1 0 2 2 0 
7 2 0 1 3 2 0 0 0 0 
8 2 0 1 2 3 0 0 0 0 
9 3 3 1 1 2 2 3 3 3 
Average 
score 
2 1.1 2 2.4 2.1 0.6 1 0.7 0.4 
 
NE-Nuclear Enlargement ; NI- Nuclear Irregularity;CC-Chromatin 
Clearing;NC-Nuclear Crowding;NG-Nuclear Grooves; PI-Nuclear 
Pseudoinclusion;Fib-Fibrosis;PB-Psammoma Bodies. 
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TABLE IX: Distribution of BRAF mutation among different types of 
Thyroid Neoplasms 
Types of neoplasms BRAF V600E positive (%) Wild Type (%) Total 
Papillary Carcinoma 9 (31) 20 (69) 29 
Follicular Neoplasm     5 (31.25)     11 (68.75) 16 
Medullary Carcinoma 0 1 (100) 1 
Anaplastic Carcinoma 0 1 (100) 1 
Total   14 (29.8) 33 (70.2) 47 
 
The above table depicts the distribution of BRAF V600E mutation among 
different types of thyroid neoplasms. 
 
 
 
 
 
 
 
 
 
 
Fig 3: Agarose Gel Electrophoresis: DNA EXTRACTION 
 
Extraction of DNA from Formalin Fixed Paraffin Embedded tissue .Run on 
Agarose gel and was confirmed with a gel doc. Photo which shows the band 
confirming the successful DNA isolation. 
Fig 4: Agarose Gel Electrophoresis: PCR AMPLIFICATION 
 
Gel electrophoresis image of PCR amplified product, by using 15F and 15R 
primers. The product size is 224bp. 
Fig 5: Poly Acrylamide Gel Electrophoresis : RESTRICTION 
DIGESTION 
 
 
 
Control: Well No - 1 (224bp) 
Wild type: Well No - 3, 5, 6, 7, 13 (120bp+ 104bp) 
Mutant: Well No - 2, 4, 8, 9, 10, 11, 12 (224bp and 224+120+104bp) 
 
 
 
  
                               
                                                                     
                                                                                             
            
 
 
  
Fig 6 : Nuclear features of  Conventional Papillary      
carcinoma. H & E (x400)    
Fig7: Micro papillary carcinoma surrounding 
normal thyroid  tissue. H&E(x100) 
Fig 8: Encapsulated follicular variant of Papillary 
Carcinoma with thin capsule and cells  
in follicular pattern. H & E (x100) 
Fig 9: Follicular adenoma with a thick capsule 
H & E (x100)                                                                           
                            
 
 
 
 
 
Fig 13: Follicular neoplasm uncertain 
malignant potential (x100)                                             
Fig 10: Signet ring cell type follicular adenoma. 
H & E (x400) 
Fig 11 : Follicular neoplasm with   minimal capsular 
invasion . H & E (x100)    
Fig 12: Hurthle cell neoplasm H & E  (x400) 
  
                                                                                          
 
 
 
                              
                            
 
                                                                                                                                                                                                                   
                            
                                                                                          
 
Fig 14:Medullary carcinoma H&E (X100) Fig 15:Medullaery carcinoma showing 
amyloid deposits in the stroma .H & E 
(x100) 
Fig 16.Anaplastic carcinoma H & E (x400)      
  
 
 
 
 
 
 
 
DISCUSSION  
49 
DISCUSSION 
 
Malignancies constituted 19.2% among all the biopsies reported at 
PSGIMSR during the study period, similar to the incidence reported from 
Chennai cancer registry [42]. The thyroid neoplasms constituted 2.16% of all 
malignancies (64 over 2953) in this institute and are similar to Chennai 
Cancer Registry reports [42] while it is higher than the 1% incidence reported 
in the Western countries [12].  
Papillary thyroid carcinomas constituted around 64% of thyroid 
neoplasms similar to the incidence reported from Chennai cancer registry 
(50-90 %). 
A report from teaching hospital, Chennai states that the incidence of 
papillary thyroid carcinoma is common in coastal areas [43]. Coimbatore is 
situated in the western part of Tamilnadu, and is a non-coastal, iodine 
deficient area as reported by a population survey conducted in 1991, by the 
Tamilnadu health and family welfare. However, the population of 
Coimbatore receives dietary iodine supplementation in the form of iodized 
salt from 1994[8]. A population survey indicates that high dietary iodine is 
associated with a high risk of thyroid neoplasms especially papillary 
carcinoma of thyroid [9]. Given the above observations, it is important to 
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plan further studies to estimate average population iodine levels in 
Coimbatore.  
Further, BRAF V600E mutation is associated with papillary thyroid 
carcinomas. Identification of this mutation has changed the algorithm of 
treatment approach to papillary thyroid carcinomas. Some of the prevailing 
local factors indicated by our biopsies including the increasing incidence, 
female preponderance, younger age at presentation and an increase in 
incidental finding of papillary carcinoma in thyroidectomy specimens along 
with the potential for altering the treatment approach to these patients, 
prompted us to do this study.  
An extensive literature search on Indian studies for BRAF mutation in 
thyroid carcinoma indicated a paucity of literature. For example, a Pubmed 
search (from1960-2010) with MESH keywords of “BRAF” and “thyroid 
neoplasm” and “India” returned no reports. Thus, we considered it to be 
important for us to do this study. 
We identified and retrieved paraffin blocks of 50 cases of thyroid 
neoplasms from archives of pathology using exclusion and inclusion criteria 
as discussed earlier. We could extract DNA from 47 cases only. DNA 
extraction was not possible for 3 cases (one each of papillary carcinoma, 
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follicular adenoma and medullary carcinoma) probably due to improper 
fixation. 
BRAF V600E mutation when present in papillary carcinoma of 
thyroid indicates a poorer outcome of the disease [26, 27]. Studies also state 
that, though this mutation can be seen in early stages, this is most often 
expressed in stage III (30%) when compared to Stage I. The expression of 
BRAF mutation in early stages indicates a possible aggressive course and 
warrants total thyroidectomy .When present in later stages of the disease, 
this is associated with a poorer outcome. 
In our study group of 30 papillary carcinomas, DNA was extracted 
from 29 cases. 9 cases were positive for BRAF V600E mutation. Hence 
31% ( 9/29cases) of papillary carcinoma thyroid expressed BRAF V600E 
mutation. Literature search states that BRAF V600E mutation is reported in 
40-45% of papillary thyroid carcinomas [22] and we infer from our study that 
there is a lesser incidence of V600E mutation expression in papillary thyroid 
carcinomas in the subset of population that received treatment in our centre 
.But interestingly we found BRAF V600E mutation in 31% of cases of 
follicular neoplasms, which is assessed and discussed further down. 
Out of 9 cases expressing V600E mutation 5 cases were in the age 
group between 20-30 years. Rossella et al [5] states that V600E is expressed 
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in papillary carcinoma occurring in older age group. In our study this is seen 
in a younger age group. BRAF V600E is known to induce a more 
aggressive phenotype and therefore this may have resulted in clinical 
expression in younger age group. As V600E mutation is also associated 
with an aggressive course, total thyroidectomy is warranted in cases 
expressing V600E in early age group. Therefore surveillance for mutation 
especially on FNA samples will prevent more repeat surgeries and help in 
better follow-up care of the patient.  
5 cases of stage I, 3 cases of stage II and 1 case of stage III expressed 
V600E mutation. The analysis of our study shows a significantly higher 
expression in stage I and stage II lesions. Therefore we reanalyzed the 
reports of papillary thyroid carcinoma. As we are in a tertiary care hospital 
with advanced facilities for patient care, radiologist and pathologist were 
probably able to detect papillary thyroid carcinoma in early stages, thereby 
explaining the higher incidence of V600E mutation in stage I papillary 
thyroid carcinomas. 
There was no significant correlation with the nuclear features and 
BRAF V600E mutation but nuclear crowding, overlapping and grooves 
were consistent finding (Table VIII). 
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As previously noted, 5 cases of follicular neoplasm expressed BRAF 
V600E mutation with a percentage incidence of 31% .Literature survey 
states that V600E mutation is not commonly seen in follicular neoplasms 
and a few studies quote no more than 1% incidence of this mutation in 
follicular neoplasms [35, 44]. Therefore reanalysis of routine H&E slides were 
done and 2 cases had focal papillary architecture with nuclear features 
which might have been overlooked in morphological assessment .Excluding 
these 2 cases the percentage incidence of V600E mutation in follicular 
neoplasm is 18.75%.As bits are given only from the representative areas and 
are not sampled extensively on a routine basis, it is likely that papillary 
carcinoma especially micro follicular type could have been missed.  
Therefore from our study, we infer that a significant number i.e., 31% 
of papillary carcinoma (9/29) and 18.75% of follicular neoplasms (3/16) 
express V600E mutation. This mutation was expressed more in stage I of 
papillary thyroid carcinoma. As BRAF mutation is associated with 
aggressive behavior, a close follow up and total thyroidectomy becomes 
essential. If mutational studies are done on cytology specimens prior to 
surgery, there might be   a reduction in number of repeat completion 
thyroidectomy procedure as total thyroidectomy is treatment of choice in 
BRAF positive cases. It might also be useful to do BRAF mutation studies  
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where there are no firm diagnosis possible by cytology. A larger prospective 
study including cytology specimen prior to surgery and surgical resection 
specimens of the same patients is essential to prove the utility of V600E 
mutation as a routine diagnostic tool. Once developed the primers become 
cost effective to the patient. Also as targeted therapies are available, 
mutational studies might be the future diagnostic methods of these tumors. 
It has been demonstrated that there is an increase in the incidence of 
papillary carcinoma where there is high iodine intake [3, 7, 15] either in diet or 
in the form of iodine supplementation in a population where there is an 
existing V600E mutation.  This raises the question over routine high iodine 
supplementation for preventing non-neoplastic conditions such as 
multinodular goiter. A larger multicentric, prospective study addressing this 
might prove to be useful. 
As our study showed an increased expression of BRAF V600E 
mutation in follicular neoplasms, a larger study of V600E mutation in 
follicular neoplasms is vital to look for a change in pattern of expression of 
mutational status in Indian population.   Algorithm of our approach to this 
study is given in Fig 17. 
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Fig 17: Algorithm of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total number of thyroid neoplasms during the study period: 64 
                    
        Selected cases: 50 
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SUMMARY AND CONCLUSION 
 
In conclusion, our study on thyroid specimens reported at 
PSGIMS&R from January 2006 to September 2009 revealed a 31% 
incidence of papillary carcinoma and 18.75% incidence of follicular 
neoplasms expressing BRAF V600E mutation. We also infer that BRAF 
V600E mutation was seen more in stage I and therefore a close follow up or 
completion thyroidectomy becomes essential. The limitation of our study 
includes small sample size. Therefore a larger multicentric study 
prospective study on both FNA and surgical specimen with long term follow 
up is essential to prove the utility of BRAF V600E mutational study as a 
routine diagnostic tool for treatment and prognostication.  
Probably ,epidemiologic survey of iodine levels and V600E mutation 
in patients with multinodular goiter and cases where incidental papillary 
thyroid carcinoma reported might go a long way in developing screening 
modalities for thyroid neoplasms and prevention of this increasing incidence 
of thyroid neoplasms. 
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MASTER CHART  
MASTER CHART 
S. 
No HP. No 
Age/ 
Sex 
Hormone 
Status Size Other features Diagnosis Stage BRAF 
1.  150/06 30/M Euthyroid 2.6cm - Minimally invasive 
follicular carcinoma 
I Mutant 
2.  458/06 48/F Euthyroid 0.4cm - Papillary microcarcinoma I Mutant 
3.  747/06 49/F Euthyroid 3.5cm Multifocal, cystic Papillary carcinoma II Wild 
4.  888/06 50/F Euthyroid NA Extrathyroidal 
extension 
Papillary carcinoma III Wild 
5.  1253/06 51/F Hyperthyroid 0.5cm Multifocal Papillary microcarcinoma I NE 
6.  1562/06 32/F Euthyroid 2.3cm - Follicular adenoma I Wild 
7.  1801/06 38/M Euthyroid 1.8cm Lymph node involvement Medullary carcinoma IV A Wild 
8.  1906/06 48/M NA 4.2cm - Follicular adenoma I NE 
9.  2093/06 23/F Euthyroid 5.5cm Multifocal Papillary carcinoma III Wild 
10.  2110/06 43/M Euthyroid 2.5cm - Follicular adenoma with papillary architecture I Mutant 
11.  2230/06 57/M Euthyroid 3.0cm - FN- UMP I Wild 
12.  2232/06 58/M Euthyroid 7.0cm - Microfollicular adenoma- 
signet ring cell type 
I Mutant 
13.  2780/06 52/F Euthyroid 
0.4- 
2.3cm Multifocal Papillary carcinoma II Mutant 
14.  2838/06 35/F Euthyroid 9.5cm - Follicular adenoma I Wild 
15.  3173/06 34/F Euthyroid 3.0cm - Follicular adenoma I Wild 
16.  29/07 51/F Euthyroid 3cm 
 
Cystic Papillary carcinoma II Wild 
17.  220/07 70/M Euthyroid 
2.0- 
4.0cm 
 
 
Multifocal 
Papillary carcinoma II Wild 
18.  307/07 38/M Euthyroid 0.5cm 
 
 
- 
Papillary microcarcinoma I Wild 
19.  600/07 67/M Hypothyroid 5.5cm 
Lymph node 
involvement 
Medullary carcinoma IV A NE 
20.  1310/07 43/F Euthyroid 3.3cm 
 
 
- 
Follicular adenoma I Wild 
21.  1560/07 50/F Euthyroid 
0.3- 
1.0cm 
 
 
Multifocal, 
cystic 
Papillary carcinoma I Wild 
22.  1572/07 30/F Euthyroid 0.4cm 
 
 
- 
 
Papillary microcarcinoma I Wild 
23.  1651/07 36/F Euthyroid 5.5cm 
- 
 
 
Follicular adenoma I Wild 
24.  2118/07 45/F Euthyroid 2.5cm 
- 
 
 
Follicular adenoma I Wild 
25.  2710/07 34/F Euthyroid 3.0cm 
- 
 
 
Follicular adenoma I Wild 
26.  2874/07 65/F Hypothyroid 1.3cm - Papillary carcinoma I Mutant 
27.  3335/07 45/F Euthyroid 6.0cm -  Hurthle cell neoplasm I Mutant 
28.  3478/07 35/F Hyperthyroid 4.5cm -  Follicular adenoma I Wild 
29.  3679/07 27/F Euthyroid 3.0cm 
- 
 
 
Papillary carcinoma II Wild 
30.  3693/07 46/F Euthroid 
0.8- 
5.0cm 
 
 
Multifocal 
 
Papillary carcinoma III Wild 
31.  648/08 55/F Euthyroid 1.0cm 
 
- 
Follicular adenoma I Wild 
32.  1101/08 30/F Hypothyroid 3.0cm - Minimally invasive 
follicular carcinoma 
I Wild 
33.  1376/08 24/F Euthyroid 5.5cm Cystic Papillary carcinoma III Wild 
34.  1422/08 53/M Euthyroid 2.0cm - Papillary carcinoma I Wild 
35.  1837/08 30/F Euthyroid 0.3cm - 
Encapsulated follicular 
variant of Papillary 
carcinoma 
I Mutant 
36.  1865/08 29/M Euthyroid 2.5cm - Papillary carcinoma II Mutant 
37.  2062/08 35/F Euthyroid 4.0cm - Follicular adenoma I Mutant 
38.  2222/08 27/F Euthyroid 2.4cm - Papillary carcinoma II Mutant 
39.  
2850/08 25/M Euthyroid 0.5cm - Papillary microcarcinoma 
I Wild 
40.  3187/08 27/F Hyperthyroid 0.5cm - Papillary microcarcinoma I Wild 
41.  4248/08 32/F Euthyroid 1.5cm - Papillary carcinoma I Wild 
42.  011/09 45/F Euthyroid 3.5cm - Papillary carcinoma II Wild 
43.  229/09 28/F Euthyroid 0.3, 1.4cm 
Multifocal, 
cystic Papillary carcinoma I Mutant 
44.  824/09 41/F Euthyroid 
0.3-
0.8cm 
Multifocal, 
stromal bone 
formation 
Papillary carcinoma I Wild 
45.  915/09 50/M Euthyroid 2.0cm Extrathyroidal 
extension 
Papillary carcinoma III Wild 
46.  920/09 59/M Euthyroid 
1.0-
3.0cm 
Multifocal Papillary carcinoma II Wild 
47.  1218/09 32/F Euthyroid 1cm Cystic Papillary carcinoma I Mutant 
48.  2548/09 20/F Euthyroid 3.5cm 
Multifocal, 
capsular and 
lymph node 
involvement 
Papillary carcinoma III Mutant 
49.  2662/09 40/F Euthyroid 11.5cm Extra thyroidal extension Anaplastic carcinoma IVB Wild 
50.  3561/09 45/F NA 3.5cm 
Lymph node 
involvement Papillary carcinoma III Wild 
 
 FN- UMP – Follicular neoplasm of uncertain malignant potential;    
 NE- DNA Not Extracted. 
